Ma Ianuali 29, 2025, ua paʻi kahi hui noiʻi Kina i kahi ʻatikala i kapa ʻia ʻo "Neoadjuvant pyrotinib and trastuzumab in HER2 positive breast cancer with no early response (NeoPaTHer): effectiveness, safety, and biomarker analysis of a prospective, multicenter, response adapted study" ma ka puke pai "Signal Transduction and Targeted Therapy".
ʻO ke kanesa umauma epidermal growth factor receptor 2 (HER2)-positive, nona ka helu o ~15% a 25% o nā maʻi umauma āpau, ua ʻike ʻia he ʻano ʻokoʻa a huhū. Hōʻike ʻia ia e ka overexpression o HER2, kahi receptor transmembrane tyrosine kinase e paipai ana i ka hoʻonui ʻana o nā cell kanesa a me ke ola. ʻO nā maʻi me ka maʻi umauma HER2-positive e kū nei i kahi pilikia kiʻekiʻe o ka hoʻi hou ʻana a me ka make i hoʻohālikelike ʻia me ka poʻe me nā ʻano maʻi umauma ʻē aʻe, e lilo ia i maʻi paʻakikī loa e mālama. Eia nō naʻe, ua loli nui ke ʻano o ka mālama ʻana i ka maʻi umauma HER2-positive i nā makahiki he iwakālua i hala iho nei, ma muli o ka hoʻolauna ʻana o nā lāʻau lapaʻau i kuhikuhi ʻia e HER2. ʻO ka mea nui, ua hoʻololi nui ka hiki ʻana mai o trastuzumab i ke ala o ka maʻi umauma HER2-positive mai kahi maʻi make loa i hoʻokahi me nā hopena ʻoi aku ka maʻalahi o ka hoʻokele a me nā hopena ʻoi aku ka maikaʻi.
Ma waena o ʻOkakopa 2020 a me Malaki 2022, ua kākau inoa ʻia he 129 mau maʻi mai nā haukapila ʻelima i loko o kēia noiʻi. No nā maʻi 129 i kākau inoa ʻia, ua ʻike ʻia he 62 (48.1%) he mau pane MRI (cohort A), 26 mau mea pane ʻole i hoʻomau me ʻehā mau pōʻaiapuni hou o TCbH (cohort B), a ua loaʻa i nā mea pane ʻole he 41 pyrotinib hou aʻe (cohort C). ʻO ka helu tpCR he 30.6% (95% CI: 20.6–43.0%) ma ka cohort A, 15.4% (95% CI: 6.2–33.5%) ma ka cohort B, a me 29.3% (95% CI: 17.6–44.5%) ma ka cohort C. Ua hōʻike nā loiloi regression logistic multivariable i nā kūlana like o ka hoʻokō ʻana i ka tpCR ma waena o nā cohorts A a me C (odds ratio = 1.04, 95% CI: 0.40–2.70). ʻAʻohe hanana ʻino hou i ʻike ʻia me ka hoʻohui ʻana o pyrotinib. Ua hōʻike nā maʻi me nā co-mutations o TP53 a me PIK3CA i nā helu haʻahaʻa o ka pane hapa mua i hoʻohālikelike ʻia me ka poʻe me ka ʻole a me ka hoʻololi ʻana o ka gene hoʻokahi (36.0% vs. 60.0%, P = 0.08). Hōʻike kēia mau ʻike e hiki i ka hoʻohui ʻana i ka pyrotinib ke pōmaikaʻi i nā maʻi i pane ʻole i ka neoadjuvant trastuzumab me ka chemotherapy. Pono ka hoʻokolokolo hou ʻana e ʻike i nā biomarkers e wānana ana i ka pōmaikaʻi o nā maʻi mai ka hoʻohui ʻana o pyrotinib.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
Email：myimmnet@163.com
Nā Kuhikuhi
https://www.nature.com/articles/s41392-025-02138-6
Ka manawa hoʻouna: Pepeluali-08-2025